SUMMARY OBJECTIVE: Nowadays, the frequency of complications is also increasing following the increasing frequency of coronary angiography and percutaneous coronary intervention. Contrast-induced nephropathy is one of the most common of these complications. This study aimed to investigate the relationship between the Osaka prognostic score, which has previously been shown to have prognostic importance in gastrointestinal malignancies, and the development of contrast-induced nephropathy. METHODS: The study retrospectively examined the data of 1,498 patients who underwent coronary angiography and percutaneous coronary intervention due to acute coronary syndrome between 2018 and 2023. Demographic characteristics and laboratory findings were retrospectively collected from patients’ charts and electronic medical records. RESULTS: Osaka prognostic score (0.84±0.25 vs. 2.2±0.32, p<0.001) was higher in patients who developed contrast-induced nephropathy. Also, Osaka prognostic score [OR 2.161 95%CI (1.101–4.241), p<0.001] was found to be an independent risk factor along with age, diabetes mellitus, systolic pulmonary artery pressure, hemoglobin, hemoglobin, C-reactive protein, albumin, N-terminal brain natriuretic peptide, and systemic immune-inflammation index. The receiver operating characteristic curve showed that the optimal cutoff value of Osaka prognostic score to predict the development of contrast-induced nephropathy was 1.5, with a sensitivity of 83.4 and a specificity of 65.9% [area under the curve: 0.874 (95%CI: 0.850–0.897, p≤0.001)]. CONCLUSION: Osaka prognostic score may be an easily calculable, user-friendly, and useful parameter to predict the development of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention after acute coronary syndromes. OBJECTIVE Nowadays Contrastinduced Contrast induced malignancies contrastinduced contrast METHODS 1498 1 498 1,49 201 2023 records RESULTS 0.84±0.25 084025 0 84 25 (0.84±0.2 vs 22032 2 32 2.2±0.32 p<0.001 p0001 p 001 Also OR 2161 161 2.16 95CI CI 95 1.101–4.241, 11014241 1.101–4.241 , 101 4 241 (1.101–4.241) age mellitus pressure hemoglobin Creactive C reactive protein albumin Nterminal N terminal peptide immuneinflammation immune inflammation index 15 5 1.5 834 83 83. 659 65 9 65.9 area 0874 874 0.87 (95%CI 08500897 850 897 0.850–0.897 p≤0.001. p≤0.001 . p≤0.001)] CONCLUSION calculable userfriendly, userfriendly user friendly, friendly user-friendly syndromes 149 49 1,4 20 202 0.84±0.2 08402 8 (0.84±0. 2203 3 2.2±0.3 p<0.00 p000 00 216 16 2.1 1101424 1.101–4.24 10 24 (1.101–4.241 1. 6 65. 087 87 0.8 0850089 85 89 0.850–0.89 p≤0.00 p≤0.001) 14 1, 0.84±0. 0840 (0.84±0 220 2.2±0. p<0.0 p00 21 2. 110142 1.101–4.2 (1.101–4.24 08 0. 085008 0.850–0.8 p≤0.0 0.84±0 084 (0.84± 22 2.2±0 p<0. p0 11014 1.101–4. (1.101–4.2 08500 0.850–0. p≤0. 0.84± (0.84 2.2± p<0 1101 1.101–4 (1.101–4. 0850 0.850–0 p≤0 0.84 (0.8 2.2 p< 110 1.101– (1.101–4 085 0.850– p≤ (0. 11 1.101 (1.101– 0.850 (0 1.10 (1.101 0.85 ( 1.1 (1.10 (1.1 (1. (1

Abstract Background There are limited data about the effect of new P2Y12 inhibitors on left ventricular ejection fraction (LVEF) after acute myocardial infarction (AMI). Objectives We aimed to investigate the effect of ticagrelor on left ventricular function, compared to clopidogrel in patients with heart failure with mildly reduced ejection fraction (HFmrEF) after AMI. Methods In this cross-sectional, single-center study, we included 251 patients with LVEF between 40% and 50% after AMI before discharge. The patients were divided into 2 groups according to the use of ticagrelor (166 patients) and clopidogrel (85 patients). At the end of the 12-month period, LVEF changes were assessed by echocardiography. P < 0.05 was considered statistically significant. Results The mean LVEF before discharge was 46.5% ± 3.6%, and no difference was observed between the ticagrelor and clopidogrel groups (p = 0.20). At the end of the first year, the mean LVEF of the patients increased to 49.8% ± 7.6% in both groups. The use of ticagrelor (β ± SE = 2.05 ± 0.93; p = 0.029), low creatinine level (β ± SE = −10.44 ± 2.35; p < 0.001), low troponin level (β ± SE = −0.38 ± 0.14; p = 0.006), and low heart rate (β ± SE = −0.98 ± 0.33; p = 0.003) were found to be independent predictors of the increase in LVEF (β ± SE 2.05 ± 0.93; 95% confidence interval: 0.21 to 3.90; p = 0.029). Conclusion In our study, ticagrelor improved left ventricular function in 12 months follow-up compared to clopidogrel in patients with HFmrEF after AMI. PY Y P2Y1 (LVEF . (AMI) (HFmrEF crosssectional, crosssectional cross sectional, sectional cross-sectional singlecenter single center study 25 40 50 166 (16 85 (8 patients. 12month month period echocardiography 005 0 05 0.0 significant 465 46 5 46.5 36 3 6 3.6% 0.20. 020 0.20 20 0.20) year 498 49 8 49.8 76 7 7.6 β 205 2.0 0.93 093 93 0.029, 0029 0.029 , 029 0.029) 1044 10 44 −10.4 2.35 235 35 0.001, 0001 0.001 001 0.001) 038 38 −0.3 0.14 014 14 0.006, 0006 0.006 006 0.006) 098 98 −0.9 0.33 033 33 0.003 0003 003 95 interval 021 21 0.2 3.90 390 90 0.029. 1 followup follow up P2Y (AMI 4 16 (1 ( 00 0. 46. 3.6 02 49. 7. 2. 0.9 09 9 002 0.02 104 −10. 2.3 23 000 0.00 03 −0. 0.1 01 0.3 3.9 39 3. −10 −0 −1 −